Arteriocyte gets FDA approval to begin critical limb ischemia clinical trial
Stem cell developer Arteriocyte has received approval from the U.S. Food and Drug Administration to begin a clinical trial for the treatment of critical limb ischemia.
Stem cell developer Arteriocyte has received approval from the U.S. Food and Drug Administration to begin a clinical trial for the treatment of critical limb ischemia.
Arteriocyte Inc. has launched a stem cell-based product that allows researchers to grow red blood cells outside the human body.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Don Brown, CEO of Cleveland-based stem cell company Arteriocyte, discusses his company's progress towards getting its therapies on the market and its priorities going forward.